Level A· Stronger Clinical EvidenceMeta-analysisEurope PMCOpen access

Stem cell-derived extracellular vesicles in premature ovarian failure: an up-to-date meta-analysis of animal studies

Luo Y., Chen J., Ning J., Sun Y., Chai Y., Xiao F.

Meta-analysis on Hair & Scalp, published in J Ovarian Res (2024) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
J Ovarian Res (2024)
Reported sample size
—
Source database
Europe PMC
PMID
39252114
PMCID
PMC11382489
DOI
10.1186/s13048-024-01489-y
Citations
7

Abstract (original English)

Background There has been a significant surge in animal studies of stem cell-derived extracellular vesicles (EVs) therapy for the treatment of premature ovarian failure (POF) but its efficacy remains unknown and a comprehensive and up-to-date meta-analysis is lacking. Before clinical translation, it is crucial to thoroughly understand the overall impact of stem cell-derived EVs on POF. Methods PubMed, EMBASE, Cochrane Library, Web of Science were searched up to February 18, 2024. The risk of bias was evaluated according to Cochrane Handbook criteria, while quality of evidence was assessed using the SYRCLE system. The PRISMA guidance was followed. Trial sequential analysis was conducted to assess outcomes, and sensitivity analysis and publication bias analysis were performed using Stata 14. Results Data from 25 studies involving 339 animals were extracted and analyzed. The analysis revealed significant findings: stem cell-derived EVs increase ovary weight (SMD = 3.88; 95% CI: 2.50 ~ 5.25; P 2 = 70%), pregnancy rate (RR = 3.88; 95% CI: 1.94 ~ 7.79; P = 0.0001; I 2 = 0%), count of births (SMD = 2.17; 95% CI: 1.31 ~ 3.04; P 2 = 69%) and counts of different types of follicles. In addition, it elevates the level of AMH (SMD = 4.15; 95% CI: 2.75 ~ 5.54; P 2 = 88%) and E2 (SMD = 2.88; 95% CI: 2.02 ~ 3.73; P 2 = 80%) expression, while reducing FSH expression (SMD = -5.05; 95% CI: -6.60

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
OvaryStem CellsAnimalsHumansDisease Models, AnimalPregnancyFemalePrimary Ovarian InsufficiencyExtracellular Vesicles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research